Targeting GPCR Signaling for Idiopathic Pulmonary Fibrosis Therapies
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
A variety of G-protein coupled receptors (GPCRs) have been implicated in the pathogenesis of pulmonary fibrosis, largely through their promotion of profibrotic fibroblast activation. In contrast, recent work has highlighted the beneficial effects Gαs-coupled GPCRs exert on reducing fibroblast activation and fibrosis. This review highlights how fibrosis promoting and inhibiting GPCR signaling converges on downstream signaling and transcriptional effectors, and how the diversity and dynamics of GPCR expression challenge efforts to identify effective therapies for IPF. Next generation strategies to overcome these challenges, focusing on target selection, polypharmacology and personalized medicine approaches, are discussed as a path toward more effective GPCR-targeted therapies for pulmonary fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modeling Development and Disease with Organoids
Clevers, H. (2016) · Cell · doi:10.1016/j.cell.2016.05.082 · Cited by 3,196
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020 · cited 4×
“IPF affects ~3 million people worldwide with a median life expectancy after diagnosis of 2–4 years and an increasing annual incidence of 3 to 18 cases per 100,000 people in the United States and Europe [8, 9].”
BackgroundInfluentialRegulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling
Yu, F.-X., Zhao, B., Panupinthu, N., Jewell, J. L., Lian, I., Wang, L. H., Zhao, J., Yuan, H., Tumaneng, K., Li, H., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.037 · Cited by 1,628
Reyfman, P. A., Walter, J. M., Joshi, N., Anekalla, K. R., McQuattie-Pimentel, A. C., Chiu, S., Fernandez, R., Akbarpour, M., Chen, C.-I., Ren, Z., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201712-2410oc · Cited by 1,203
Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span
Misharin, A. V., Morales-Nebreda, L., Reyfman, P. A., Cuda, C. M., Walter, J. M., McQuattie-Pimentel, A. C., Chen, C.-I., Anekalla, K. R., Joshi, N., Williams, K. J. N., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162152 · Cited by 1,133
Polypharmacology: Challenges and Opportunities in Drug Discovery: Miniperspective
Anighoro, A., Bajorath, J., & Rastelli, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006463 · Cited by 1,131
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005 · cited 1×
“Nintedanib acts as an ATP-competitive inhibitor of fibroblast growth factor receptor (FGFR)-1, vascular endothelial growth factor receptor (VEGFR)-2, platelet-derived growth factor receptors (PDGFRs), Flt-3 and members of the Src-family, such as Src, Lyn and Lck [83],[84].”
BackgroundMechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis
Liu, F., Lagares, D., Choi, K. M., Stopfer, L., Marinković, A., Vrbanac, V., Probst, C. K., Hiemer, S. E., Sisson, T. H., Horowitz, J. C., et al. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00300.2014 · Cited by 874
Self-citationTager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., et al. (2008) · Nature Medicine · doi:10.1038/nm1685 · Cited by 823 · cited 1×
“For example, LPA has been shown to be increased in the bronchial alveolar lavage fluid (BALF) [29], and exhaled breath condensate (EBC) [25] from patients with idiopathic pulmonary fibrosis, and in rodent models of pulmonary fibrosis [26–28].”
BackgroundBUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1874oc · Cited by 718
How Ligands Illuminate GPCR Molecular Pharmacology
Wacker, D., Stevens, R. C., & Roth, B. L. (2017) · Cell · doi:10.1016/j.cell.2017.07.009 · Cited by 560 · cited 1×
“The number of drugs which target GPCRs is very large; however the number of distinct GPCRs targeted by those drugs is actually only a small percentage of the more than 800 unique GPCRs [101].”
BackgroundTreatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial
Raghu, G., Behr, J., Brown, K. K., Egan, J. J., Kawut, S. M., Flaherty, K. R., Martinez, F. J., Nathan, S. D., Wells, A. U., Collard, H. R., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-9-201305070-00003 · Cited by 553
BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Behr, J., Brown, K. K., du Bois, R. M., Lancaster, L., de Andrade, J. A., Stähler, G., Leconte, I., Roux, S., & Raghu, G. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-732oc · Cited by 500
Selectivity determinants of GPCR–G-protein binding
Flock, T., Hauser, A. S., Lund, N., Gloriam, D. E., Balaji, S., & Babu, M. M. (2017) · Nature · doi:10.1038/nature22070 · Cited by 384 · cited 3×
“In contrast to all other classes of G-proteins discussed above, Gαs/cAMP signaling promotes phosphorylation and inhibition of YAP/TAZ nuclear translocation [37, 50], as well as reduced MRTF nuclear localization [51].”
BackgroundMacitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
Raghu, G., Million-Rousseau, R., Morganti, A., Perchenet, L., Behr, J., & the MUSIC Study Group (2013) · European Respiratory Journal · doi:10.1183/09031936.00104612 · Cited by 277
Knipe, R. S., Tager, A. M., & Liao, J. K. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009381 · Cited by 233
Palmer, S. M., Snyder, L., Todd, J. L., Soule, B., Christian, R., Anstrom, K., Luo, Y., Gagnon, R., & Rosen, G. (2018) · Chest · doi:10.1016/j.chest.2018.08.1058 · Cited by 202
Novel Allosteric Modulators of G Protein-coupled Receptors
Gentry, P. R., Sexton, P. M., & Christopoulos, A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.662759 · Cited by 199
cAMP and Epac in the regulation of tissue fibrosis
Insel, P. A., Murray, F., Yokoyama, U., Romano, S., Yun, H., Brown, L., Snead, A., Lu, D., & Aroonsakool, N. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01847.x · Cited by 175 · cited 2×
“Through the use of the cAMP enhancing pharmaco-tool forskolin, elevated cAMP was identified as a means to block transforming growth factor beta (TGFβ) induced fibroblast activation [45].”
BackgroundMethodSpeight, P., Kofler, M., Szászi, K., & Kapus, A. (2016) · Nature Communications · doi:10.1038/ncomms11642 · Cited by 144 · cited 17×
“In a recent study, TGFβ induced repression of GPCR encoding genes including prostanoid receptors (PTGER2, PTGER4, and PTGIR), adenosine receptors (ADORA2A and ADORA2B), as well as the beta-2 adrenergic receptor (ADRB2).”
BackgroundInfluentialMiranda, M. Z., Bialik, J. F., Speight, P., Dan, Q., Yeung, T., Szászi, K., Pedersen, S. F., & Kapus, A. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.780502 · Cited by 103
Haak, A. J., Tsou, P.-S., Amin, M. A., Ruth, J. H., Campbell, P., Fox, D. A., Khanna, D., Larsen, S. D., & Neubig, R. R. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213520 · Cited by 103
Self-citationTGFβ-induced fibroblast activation requires persistent and targeted HDAC-mediated gene repression
Jones, D. L., Haak, A. J., Caporarello, N., Choi, K. M., Ye, Z., Yan, H., Varelas, X., Ordog, T., Ligresti, G., & Tschumperlin, D. J. (2019) · Journal of Cell Science · doi:10.1242/jcs.233486 · Cited by 77
Self-citationDocosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis
Montesi, S. B., Mathai, S. K., Brenner, L. N., Gorshkova, I. A., Berdyshev, E. V., Tager, A. M., & Shea, B. S. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-5 · Cited by 66
Cited by
The Role of Myofibroblasts in Physiological and Pathological Tissue Repair
Schuster, R., Younesi, F., Ezzo, M., & Hinz, B. (2023) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041231 · Cited by 232
Implant Fibrosis and the Underappreciated Role of Myofibroblasts in the Foreign Body Reaction
Noskovicova, N., Hinz, B., & Pakshir, P. (2021) · Cells · doi:10.3390/cells10071794 · Cited by 184
Reininger, D., Fundel‐Clemens, K., Mayr, C. H., Wollin, L., Laemmle, B., Quast, K., Nickolaus, P., & Herrmann, F. E. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17303 · Cited by 48
“In recent reports, it has been postulated that impaired cAMP signalling in IPF may be attributed to resistance to prostaglandin E2 or dysregulated signalling of GPCRs (Haak et al., 2020; Huang et al., 2010).”
Schmidt, M., Cattani-Cavalieri, I., Nuñez, F. J., & Ostrom, R. S. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.05.002 · Cited by 30
Metadata
- Authors
- Haak, A. J., Ducharme, M. T., Diaz Espinosa, A. M., & Tschumperlin, D. J.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 41
- Issue
- 3
- Pages
- 172-182
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W3003289036
- Cited by
- 65
- References
- 25
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.